Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a capital raising
Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

March 05, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge advises TSG on the acquisition of Processkontroll GT

 TSG, a European leader in technical services for sustainable mobility solutions and critical energy infrastructure, has acquired Processkontroll GT, a specialist in compressed and liquid gas infrastructure.
June 01, 2026

Vinge has advised Mirova with the financing of the Fågelås, Dållebo, and Boarp wind farms

 The financing, provided by Danske Bank and La Banque Postale, consists of multiple facilities totalling approximately EUR 100 million, including, among other things, a long-term amortising loan and guarantee facilities.
June 01, 2026

Vinge has advised Nordion Energi AB in connection with the acquisition of shares in Kalmar Energi

 Nordion Energi acquires E.ON Sverige AB’s entire stake in Kalmar Energi and in connection with the completion of such, divest Kalmar Energi’s electricity retail business to Siljansvik AB (publ).
May 29, 2026